Business
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego, Calif. Allogene’s presentations at AACR highlight the potential of allogeneic CAR T to expand access, simplify delivery, and enable broader a
About this update from Allogene Therapeutics, Inc.
[{"type":"image","alt":"Allogene Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allogene Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":126,"url":"https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fF5s8tDZfOcdddQ1DBkmiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3Ng--/https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030","width":300,"height":126}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego, Calif.","length":365,"tagName":"p"},{"type":"text","content":"Allogene’s presentations at AACR highlight the potential of allogeneic CAR T to expand access, simplify delivery, and enable broader application of cell therapy across diseases when its inherent advantages are fully leveraged. The Company will participate in several AACR 2026 scientific forums, including:","length":306,"tagName":"p"},{"type":"text","content":"Poster: Preclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple MyelomaPresenter: Mark K. O’Dair, PhD, AllogeneSession Title: CAR T Cell Targets and TME ReprogrammingPoster Number: 1535Location: Poster Section 7, Board 17Session Date and Time: Monday, April 20, 9:00am-12:00pm PT","length":320,"tagName":"p"},{"type":"text","content":"Based on its foundational work in oncology, Allogene is extending its Dagger® technology into autoimmune disease, applying its gene-edited, dual-targeting CAR T approach to target both BCMA and CD70 on malignant plasma cells as well as selectively eliminate alloreactive immune cells to promote durable persistence with reduced need for chemotherapy-based lymphodepletion. This strategy builds on the Company’s expertise in allogeneic cell therapy in advanced renal cell carcinoma and is designed to deliver a readily available, off-the-shelf treatment with the potential to transform how both cancer and autoimmune diseases are treated.Major Symposium: Off-the-Shelf Cell Thera...